Mode
Text Size
Log in / Sign up
N/A N=64 Randomized Triple-blind Treatment

Clinical Efficacy and Human Factors Validation Testing of the Erchonia EVRL for Providing Temporary Relief of Diabetic Peripheral Neuropathy Foot Pain

Neuropathy, Diabetic · Neuropathy;Peripheral · Neuropathy, Painful

Enrolled (actual)
64
Serious AEs
0.0%
Results posted
Aug 2025
Primary outcome: Primary: Number of Participants With a 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS) — 24; 9 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Erchonia® EVRL™ (Device); Placebo Laser (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Erchonia Corporation
Primary completion
Oct 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With a 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS)
24; 9
SECONDARY
Satisfaction With Study Outcome
20; 8
SECONDARY
Four Weeks Post Procedure Change in Foot Pain Visual Analog Scale (VAS) Score
-34.32; -13.41

Summary

The purpose of this clinical study is to determine the effectiveness of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Company), in providing prescription home use application for temporary relief of diabetic neuropathy foot pain in individuals diagnosed with diabetic neuropathy by a suitably qualified and licensed health professional.

Eligibility Criteria

Inclusion Criteria

  • Previously diagnosed with diabetes induced peripheral neuropathy by a suitably qualified and licensed health professional within the past 6 months
  • Over the age of 18 years of age
  • Able to read and write English.
  • Constant feet pain on-going over at least the past 3 months.
  • If using analgesics (pain medication), you must be on a stable analgesic regimen (i.e., no changes to the prescribed analgesic regimen) over a period of at least 14 days prior to enrollment; and willing and able to not have planned upward dose titration of analgesics during the study period. You may elect to decrease analgesic use during the study. Cannabis prescribed for medicinal purposes would qualify as an analgesic in this context.
  • Willing and able to refrain from engaging in any non-study procedure therapies for the management of foot pain throughout the course of study participation, including conventional therapies such as physical therapy, occupational therapy and hot or cold packs, as well as alternative therapies such as chiropractic care and acupuncture.
  • Agrees to refrain from taking a dosage of analgesic (pain medication) for at least 6 hours before a scheduled VAS foot pain rating is to be recorded.
  • Subjects' degree of foot pain on the 0-100 VAS, with "0" being no pain and "100" being worst pain imaginable, is 50 or greater.

Exclusion Criteria

  • Pregnant or think you might be pregnant.
  • Open wounds (sores, cuts, ulcers, etc) around the feet
  • Cancerous growths around the feet
  • Difficulty with hand dexterity sufficient to impact ability to administer treatments with the laser such as from severe arthritis in the hands, Multiple Sclerosis, Cerebral Palsy, Parkinson's Disease, Huntington's Disease, etc.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05291975). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search